Algo version: 0.98b
GlaxoSmithKline is listed at the NSE Exchange
GlaxoSmithKline [GLAXO.NS]
NSE Sector: Healthcare Industry:Drug Manufacturers—General

Is GlaxoSmithKline stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

Yes, GlaxoSmithKline pays dividends. Last time was Sunday 28th of July 2024 where the investors holding the stock on Friday 31st of May 2024 were paid INR32 per share. Over the last 22 times between 2003 and 2024, GlaxoSmithKline has paid INR740.5 with an average of INR33.66 per share.

Sorry, we do not have any analyst data for this ticker

We cannot find data for GlaxoSmithKline 10 years ago, but if you had invested on Monday 9th of September 2019 when the price was INR1 329.05, you would have made a profit of INR1 502.55 per share or 113.05%

Yes, the average daily trading liquidity for GlaxoSmithKline is INR151 002 thousand. You should therefore be able to get in and out of your positions relatively fast.

GlaxoSmithKline has no real debt, which is good in periods of high inflation. With a high cash flow to debt ratio of 5.53, the company's ability to pay off the debt is good. GlaxoSmithKline has a good net profit margin of 17.08% and should have high tolerances against inflation.

We have calculated the inflation risk for GlaxoSmithKline to be low [0.1 of 1]

US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.